Ciliary body melanoma

From WikiMD's Wellness Encyclopedia

Ciliary Body Melanoma is a rare form of eye cancer that originates in the ciliary body, a part of the eye responsible for producing the fluid in the eye, also known as aqueous humor. This type of melanoma is a subtype of uveal melanoma, which is the most common primary intraocular malignancy in adults.

Epidemiology[edit | edit source]

Ciliary body melanoma is a rare disease, accounting for approximately 6% of all uveal melanomas. The incidence rate is estimated to be around 0.2 cases per 100,000 people per year. It is more common in adults, with a median age of diagnosis around 55 years.

Pathophysiology[edit | edit source]

The ciliary body contains melanocytes, which are cells that produce the pigment melanin. In ciliary body melanoma, these melanocytes become cancerous and start to grow uncontrollably. The exact cause of this transformation is not fully understood, but it is believed to involve genetic mutations and possibly exposure to ultraviolet (UV) radiation.

Clinical Presentation[edit | edit source]

Patients with ciliary body melanoma often present with symptoms such as blurred vision, a visible mass in the eye, or pain. However, in some cases, the tumor may be discovered incidentally during a routine eye examination.

Diagnosis[edit | edit source]

The diagnosis of ciliary body melanoma is typically made based on clinical examination and imaging studies, such as ultrasound, magnetic resonance imaging (MRI), or computed tomography (CT) scan. A biopsy may be performed to confirm the diagnosis.

Treatment[edit | edit source]

The treatment of ciliary body melanoma depends on the size and location of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, or in some cases, enucleation (removal of the eye).

Prognosis[edit | edit source]

The prognosis for ciliary body melanoma is generally poor, with a 5-year survival rate of approximately 50%. Factors that may affect prognosis include the size of the tumor, the presence of metastasis, and the patient's overall health.

See Also[edit | edit source]

Contributors: Prab R. Tumpati, MD